

# AGI-5198

**Catalog No: tcsc1429** 

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

**Specifications** 

CAS No:

1355326-35-0

Formula:

 $C_{27}H_{31}FN_4O_2$ 

**Pathway:** Metabolic Enzyme/Protease

**Target:** 

Isocitrate Dehydrogenase (IDH)

# Purity / Grade:

>98%

### Solubility:

DMSO : ≥ 34 mg/mL (73.50 mM)

#### **Alternative Names:**

IDH-C35

## **Observed Molecular Weight:**

462.56

Copyright 2021 Taiclone Biotech Corp.



# **Product Description**

AGI-5198 is a novel **R132H-IDH1** inhibitor, used for cancer treatment.

*In Vitro:* Measurements of R-2HG concentrations in pellets of TS603 glioma cells demonstrates dose-dependent inhibition of the mutant IDH1 enzyme by AGI-5198. AGI-5198 does not impair colony formation of two patient-derived glioma lines that express only the wild-type IDH1 allele (TS676 and TS516)<sup>[1]</sup>. Cancer cells heterozygous for the IDH1(R132H) mutation exhibits less IDH-mediated production of NADPH, such that after exposure to ionizing radiation (IR), there are higher levels of reactive oxygen species, DNA double-strand breaks, and cell death compared with IDH1 wild-type cells. These effects are reversed by the IDH1(R132H) inhibitor AGI-5198<sup>[2]</sup>.

*In Vivo:* AGI-5198 (450 mg/kg, p.o.) causes 50 to 60% growth inhibition of the tumor growth from human glioma xenografts. Tumors from AGI-5198- treated mice show reduced staining with an antibody against the Ki-67 protein. AGI-5198 does not affect the growth of IDH1 wild-type glioma xenografts<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.